Optimi Health Appoints Chief Science Officer
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) has appointed Mr. Justin D. Kirkland as Chief Science Officer. With extensive expertise in natural products and drug formulation, Kirkland is expected to enhance Optimi's research in psilocybin formulations. The company is nearing completion of its 20,000 sq. ft. facility in Princeton, BC, and plans to conduct human dosing studies at the University of Calgary. Optimi emphasizes the use of all-natural ingredients, aiming for a competitive edge in the health and wellness market.
- Appointment of Justin D. Kirkland as Chief Science Officer brings extensive expertise in natural products and drug formulation.
- Nearing completion of a 20,000 sq. ft. facility to enhance research and product development.
- Focus on all-natural psilocybin formulations differentiates the company from synthetic competitors.
- Appointment of a new CSO may pose transitional challenges and impact continuity of ongoing projects.
Company welcomes leadership oversight of new product research, formulations & trials
VANCOUVER, British Columbia, May 26, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the engagement of Mr. Justin D. Kirkland to the position of Chief Science Officer with immediate effect.
Mr Kirkland is a chemist with specialized experience in natural products, small molecules, peptide synthesis, analytical chemistry, and drug formulations for improved bioavailability. He was recently awarded a U.S. patent for the improved synthesis of the ergoline, 2-bromo-LSD; useful in treating cluster headaches. He lately served as CEO of Las Vegas-based Fristoe Pharmaceuticals, an FDA registered wholesale drug distributor, and previously oversaw product development for Wells Pharmacy Network from their base in Florida; he was the lead scientific investigator regarding synthetic peptides at Tailor Made Health in Kentucky, and managed functional food manufacturing at Nuka Foods in Colorado and founded Kilochem’s efforts in Illinois. Since 2007, he founded and operated Nutraseeds dietary supplements and cosmetics program. Kirkland’s career includes training support, sales, analytics, and related consulting services since 1998.
Optimi’s JJ Wilson, (Chairman of the Board), states, “We felt it important to invest time to find a suitable leader to oversee and coordinate the multiple and overlapping aspects of our research efforts. We were delighted to identify a candidate that fit with our approach of aggressively pursuing IP and patentable all-natural psilocybin formulations so readily. Justin’s overall background, interest, and experience in the development of innovative natural drug products is ideally suited to assist our rapid growth in the research and development of natural and novel psilocybin-based formulations. The fact he has extensive experience with functional product development and manufacturing is a significant plus as we begin our upcoming dosing study in humans at the University of Calgary. On behalf of the whole team, we welcome him and look forward to working together as we grow our business of human optimization.”
As previously stated, Optimi’s overarching philosophy and commitment to the use of all-natural ingredients in its products is a key differentiator compared to those industry competitors who have committed to the production of laboratory produced synthetic psilocybin compounds. To further these efforts, the company is nearing completion and official commissioning of its 20,000 sq. ft. purpose-built facilities in Princeton, BC. This effort, along with an accelerated need to coordinate activities with the previously announced IMPACT program and research relationship with Numinus Wellness are extraordinary opportunities requiring effective leadership in order to rapidly meet the requisite steps towards the future commercialization of psilocybin-based formulations.
On Behalf of the Board of Directors, Optimi Health Corp.
Mike Stier
President, Chief Executive Officer and Director
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
Find out more at: https://optimihealth.ca/.
FOR FURTHER INFORMATION CONTACT:
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/
FORWARD‐LOOKING STATEMENTS
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, "forward‐looking statements") that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "expects", "will continue", "is anticipated", "anticipates", "believes", "estimated", "intends", "plans", "forecast", "projection", "strategy", "objective" and "outlook") are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements" and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
FAQ
What is the significance of Justin D. Kirkland's appointment at Optimi Health Corp?
What are the upcoming plans for Optimi Health Corp following the leadership change?
How does Optimi's new facility impact its operations?
What distinguishes Optimi Health Corp in the psilocybin market?
